---
title: 'Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post
  hoc 18-month follow-up of a phase 1 trial'
date: '2023-08-17'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37592106/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20230818180856&v=2.17.9.post6+86293ac
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Idecabtagene vicleucel (ide-cel) is a B-cell-maturation antigen (BCMA)-directed
  chimeric antigen receptor T cell therapy. We performed a post hoc analysis of a
  single-arm phase 1 multicenter study in relapsed/refractory multiple myeloma (CRB-401)
  (n = 62; median follow-up, 18.1 months). The primary endpoint was safety outcomes,
  and secondary endpoints included overall response rate (ORR), complete response
  (CR) and very good partial response (VGPR). The study met its primary endpoint with
  ...
disable_comments: true
---
Idecabtagene vicleucel (ide-cel) is a B-cell-maturation antigen (BCMA)-directed chimeric antigen receptor T cell therapy. We performed a post hoc analysis of a single-arm phase 1 multicenter study in relapsed/refractory multiple myeloma (CRB-401) (n = 62; median follow-up, 18.1 months). The primary endpoint was safety outcomes, and secondary endpoints included overall response rate (ORR), complete response (CR) and very good partial response (VGPR). The study met its primary endpoint with ...